| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H8N4OS |
| Molecular Weight | 268.294 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=CC=C3N=CSC3=C2\C1=C\C4=CN=CN4
InChI
InChIKey=VFBGXTUGODTSPK-BAQGIRSFSA-N
InChI=1S/C13H8N4OS/c18-13-8(3-7-4-14-5-15-7)11-9(17-13)1-2-10-12(11)19-6-16-10/h1-6H,(H,14,15)(H,17,18)/b8-3-
| Molecular Formula | C13H8N4OS |
| Molecular Weight | 268.294 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
C16 (PKRi) is a selective inhibitor of the enzyme double-stranded RNA-dependent protein kinase (PKR). PKRi prevents striatal neurodegeneration and improves behavioral outcomes in a chemically induced mouse model of Huntington's disease, the efffect mediated by off-target inhibition of CDKs. PKRi restored memory deficit in a mouse model of Alzheimer's disease. In a mouse model of colon-26 adenocarcinoma, treatment with C16 lead to a significantly higher level of blood glucose and lower level of serum triglyceride compared with placebo group, which indicates potential use for alleviation of cachexia.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
In the model of Huntington's disease, C16 was administered to mice intraperioneally at the dose of 0.27 mg/kg once a day for 5 days.
Route of Administration:
Intraperitoneal
